Filippo de Marinis

46.1k total citations · 13 hit papers
450 papers, 19.0k citations indexed

About

Filippo de Marinis is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Filippo de Marinis has authored 450 papers receiving a total of 19.0k indexed citations (citations by other indexed papers that have themselves been cited), including 392 papers in Pulmonary and Respiratory Medicine, 330 papers in Oncology and 63 papers in Molecular Biology. Recurrent topics in Filippo de Marinis's work include Lung Cancer Treatments and Mutations (362 papers), Lung Cancer Research Studies (182 papers) and Lung Cancer Diagnosis and Treatment (160 papers). Filippo de Marinis is often cited by papers focused on Lung Cancer Treatments and Mutations (362 papers), Lung Cancer Research Studies (182 papers) and Lung Cancer Diagnosis and Treatment (160 papers). Filippo de Marinis collaborates with scholars based in Italy, United States and Spain. Filippo de Marinis's co-authors include Joachim von Pawel, U. Gatzemeier, Giorgio V. Scagliotti, Keunchil Park, Christian Manegold, Antonio Passaro, Jose R. Pereira, Cesare Gridelli, Tony Mok and Johan Vansteenkiste and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Filippo de Marinis

436 papers receiving 18.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

2008 2.5k citations Giorgio V. Scagliotti, Purvish Parikh et al. Journal of Clinical Oncology profile →
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

2004 1.9k citations Jose R. Pereira, Filippo de Marinis et al. Journal of Clinical Oncology profile →
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

2009 1.0k citations Robert Pirker, Jose R. Pereira et al. profile →
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer

2002 739 citations Giorgio V. Scagliotti, Filippo de Marinis et al. Journal of Clinical Oncology profile →
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer

2020 649 citations Alice T. Shaw, Todd M. Bauer et al. profile →
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

2011 453 citations Robert Pirker, Jose R. Pereira et al. The Lancet Oncology profile →
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

2012 447 citations Luis Paz‐Ares, Filippo de Marinis et al. The Lancet Oncology profile →
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

2013 438 citations Luis Paz‐Ares, Filippo de Marinis et al. Journal of Clinical Oncology profile →
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

2018 336 citations Fabrice Barlési, Johan Vansteenkiste et al. The Lancet Oncology profile →
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

2019 319 citations Rafał Dziadziuszko, Tony Mok et al. Journal of Thoracic Oncology profile →
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

2023 263 citations Roy S. Herbst, Shun Lü et al. profile →
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

2022 129 citations Benjamin Solomon, Todd M. Bauer et al. profile →
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

2024 118 citations Benjamin Solomon, Geoffrey Liu et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Filippo de Marinis

Since Specialization

Citations

This map shows the geographic impact of Filippo de Marinis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Filippo de Marinis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Filippo de Marinis more than expected).

Fields of papers citing papers by Filippo de Marinis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Filippo de Marinis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Filippo de Marinis. The network helps show where Filippo de Marinis may publish in the future.

Co-authorship network of co-authors of Filippo de Marinis

This figure shows the co-authorship network connecting the top 25 collaborators of Filippo de Marinis. A scholar is included among the top collaborators of Filippo de Marinis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Filippo de Marinis. Filippo de Marinis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Uncommon and Rare EGFR Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art 2024 ·Cancers ·Federico Pio Fabrizio, Ilaria Attili, Filippo de Marinis	1
2	1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo) 2024 ·Annals of Oncology ·Benjamin Solomon, Yi‐Long Wu, Rafał Dziadziuszko, Fabrice Barlési, Makoto Nishio, (unknown), Hidehito Horinouchi, Maximilian J. Hochmair, Filippo de Marinis, M.R. Migliorino, (unknown), Hakan Harputluoğlu, (unknown), Krittiya Korphaisarn, (unknown), T Lohmann, (unknown), V.R. Archer, Małgorzata Nowicka, Johannes Noé	1
3	Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study breakdown → 2024 ·Journal of Clinical Oncology ·Benjamin Solomon, Geoffrey Liu, Enriqueta Felip, Tony Mok, Ross A. Soo, Julien Mazières, Alice T. Shaw, Filippo de Marinis, Yasushi Goto, Yi‐Long Wu, Dong‐Wan Kim, Jean-François Martini, Rossella Messina, Jolanda Paolini, Anna Polli, Despina Thomaidou, Francesca Toffalorio, Todd M. Bauer	118
4	The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics 2024 ·Genes ·Pamela Trillo Aliaga, Ester Del Signore, (unknown), Gianluca Spitaleri, (unknown), Ilaria Attili, Carla Corvaja, (unknown), Antonio Passaro, Filippo de Marinis	1
5	Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials 2024 ·Cancers ·Ilaria Attili, (unknown), Gianluca Spitaleri, Carla Corvaja, Pamela Trillo Aliaga, Ester Del Signore, (unknown), (unknown), Antonio Passaro, Filippo de Marinis	4
6	Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs” 2024 ·Cancers ·Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, Ester Del Signore, Carla Corvaja, (unknown), (unknown), Antonio Passaro, Filippo de Marinis	2
7	Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. 2023 ·Journal of Clinical Oncology ·James Chih‐Hsin Yang, (unknown), Jong Seok Lee, Yun Fan, Filippo de Marinis, Isamu Okamoto, Takako Inoue, (unknown), Zhang Li, Cheng‐Ta Yang, Emmanuel de la Mora Jimenez, Jianying Zhou, M. Pérol, Ki Hyeong Lee, David Vicente, Eiki Ichihara, Gregory J. Riely, Yiwen Luo, Niyati Bhagwati, Shun Lü	50
8	1358P Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC 2023 ·Annals of Oncology ·Ernest Nadal, (unknown), Valentina Guarneri, (unknown), (unknown), Marie Wislez, Cheng Huang, Chong Kin Liam, Julien Mazières, Lye Mun Tho, Hidetoshi Hayashi, Nguyen Viet Nhung, Puey Ling Chia, Filippo de Marinis, (unknown), Svenja Adrian, Barbara Ellers‐Lenz, Karin Berghoff, Niki Karachaliou, Yi‐Long Wu	1
9	OA15.04 Comparison of Digital Vs Manual PD-L1 Tumour Cell Scoring on SP263-Stained Whole Imaging Slides from IMpower110 2023 ·Journal of Thoracic Oncology ·Roy S. Herbst, Daniel Ruderman, James F. Conway, Hen Prizant, (unknown), (unknown), (unknown), Michael Montalto, Andrew H. Beck, Ilan Wapinski, Luciana Molinero, Md Robed Amin, Tien Hoang, Marcus Ballinger, Filippo de Marinis, Giuseppe Giaccone, Jacek Jassem, Jennifer M. Giltnane, Manoj Srivastava, David R. Spigel	2
10	Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results 2023 ·Clinical Lung Cancer ·Filippo Lococo, Alessandra Cancellieri, Marco Chiappetta, Alessandro Leonetti, Giuseppe Cardillo, Francesca Zanelli, Giuseppe Mangiameli, Luca Toschi, (unknown), Francesco Jacopo Romano, Giovanni Leuzzi, Claudia Proto, Lorenzo Spaggiari, Filippo de Marinis, Emanuele Vita, Luca Ampollini, Stefano Margaritora, Marcello Tiseo, Emilio Bria	4
11	LBA63 SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC) 2023 ·Annals of Oncology ·Hossein Borghaei, Melissa L. Johnson, Edward B. Garon, Kai He, David Planchard, Martin Reck, Sanjay Popat, Roy S. Herbst, Ticiana Leal, Daphne W. Dumoulin, Filippo de Marinis, Charles H. Reynolds, Willemijn S.M.E. Theelen, Ivor Percent, (unknown), (unknown), Ronald Shazer, Xin Yan, (unknown), (unknown)	4
12	LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation 2023 ·Annals of Oncology ·Marina Chiara Garassino, Willemijn S.M.E. Theelen, Robert M. Jotte, Janessa Laskin, Filippo de Marinis, Carlos Aguado, Firas Badin, Izabela Chmielewska, Maximilian J. Hochmair, Shun Lu, Ernest Nadal, Gyula Ostoros, Enriqueta Felip, Alexander I. Spira, (unknown), Jinghua He, Richard C. Chao, Pasi A. Jänne	37
13	1468P Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial 2023 ·Annals of Oncology ·Martin Reck, Ana Laura Ortega Granados, Filippo de Marinis, Qing Shen, Susan Boklage, C. Dabrowski, (unknown), Oren Meyers	1
14	MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target 2023 ·Cancers ·Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, Ester Del Signore, Carla Corvaja, Chiara Corti, (unknown), Antonio Passaro, Filippo de Marinis	12
15	Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features 2021 ·Cancers ·Antonio Passaro, Silvia Novello, Diana Giannarelli, Emilio Bria, Domenico Galetta, Alain Gelibter, Maria Lucia Reale, Simona Carnio, Emanuele Vita, (unknown), Pamela Pizzutilo, Valeria Stati, Ilaria Attili, Filippo de Marinis	14
16	Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study 2020 ·Kölner Universitäts PublikationsServer (Universität zu Köln) ·Jennifer Moriatis Wolf, Tobias R. Overbeck, Ji‐Youn Han, Maximilian J. Hochmair, Filippo de Marinis, Kadoaki Ohashi, Egbert F. Smit, David A. Power, Edward B. Garon, Harry J.M. Groen, Daniel S.W. Tan, Maeve Waldron-Lynch, Sylvie Le Mouhaër, (unknown), Marco Giovannini, Rebecca S. Heist	8
17	Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib 2015 ·Clinical Cancer Research ·Justin F. Gainor, Daniel Shao-Weng Tan, (unknown), Benjamin Solomon, (unknown), Chiara Lazzari, Filippo de Marinis, Gianluca Spitaleri, Katherine R. Schultz, Luc Friboulet, Beow Y. Yeap, Jeffrey A. Engelman, Alice T. Shaw	135
18	Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials 2014 ·Lung Cancer ·Giorgio V. Scagliotti, Cesare Gridelli, Filippo de Marinis, Michael Thomas, Mircea Dediu, Jean-Louis Pujol, C. Manegold, Belén San Antonio, Patrick Peterson, William J. John, Nadia Chouaki, Carla Visseren‐Grul, Luis Paz‐Ares	18
19	EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study breakdown → 2011 ·The Lancet Oncology ·Robert Pirker, Jose R. Pereira, Joachim von Pawel, Maciej Krzakowski, Rodryg Ramlau, Keunchil Park, Filippo de Marinis, Wilfried Eberhardt, Luis Paz‐Ares, Stephan Störkel, (unknown), Anja von Heydebreck, Ilhan Celik, Kenneth J. O’Byrne	453
20	Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer breakdown → 2008 ·Journal of Clinical Oncology ·Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, U. Gatzemeier, Raghunadharao Digumarti, Mauro Zukin, (unknown), Anders Mellemgaard, Keunchil Park, (unknown), Janusz Rolski, Tuncay Göksel, Filippo de Marinis, Lorinda Simms, Katherine P. Sugarman, David R. Gandara	2487

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact